source
- CG preps new, expanded bladder cancer plans with FDA after ph. 3 winCG Oncology showed in a late-stage study that its immunotherapy cretostimogene reduced the risk of tumor recurrence in certain patients with non-muscle invasive bladder cancer following surgery.Fierce Biotech · 9h ago↗ source
- FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entryThe U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…